WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won"Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been...
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target
SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day,
WuXi Biologics reaffirms its commitment to sustainability through responsible
operations and efficient, circular water‑use practices that reduce
environmental impact.
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excelle...
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025...
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an inn...
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody
SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific ...
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and auto...
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufactur...
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility ac...
WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security
SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recogn...
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This to...
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index Series, marking the fifth consecutive year the company h...
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)
WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Türkiye İlaç ve ...
